Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. For many people living with this condition, finding treatments that keep the disease stable while maintaining a good quality of life is a major priority. This research focuses on how different combinations of medications can improve the time patients live without their cancer progressing.
A large Phase 3 clinical trial was conducted to compare three different treatment paths for patients with CLL who did not have specific genetic mutations called TP53 aberrations. The study included 926 participants. One group received a combination of venetoclax and rituximab (RV). A second group received venetoclax and obinutuzumab (GV). A third group received a triple combination of venetoclax, obinutuzumab, and ibrutinib (GIV). These three groups were compared against a standard chemotherapy and immunotherapy treatment known as CIT.
The results showed that the venetoclax-based treatments performed better at keeping the disease from progressing over time. Specifically, after five years, about 81.3% of patients in the triple combination group (GIV) and 69.8% in the GV group remained stable compared to only 50.7% in the standard chemotherapy group. While these combinations were more effective at preventing progression, the study did not find a significant difference in overall survival rates between any of the groups after five years. This means that while the new treatments kept the cancer from growing for longer periods, the total number of survivors remained similar across all treatment types.
Safety and quality of life are also important factors for patients. The study found that both the GV and RV combinations led to faster improvements in a patient's quality of life compared to standard chemotherapy. However, the triple combination (GIV) had more initial symptoms related to the treatment, meaning those patients saw their quality of life improve later than those on other venetoclax plans. Regarding risks, some patients on standard chemotherapy experienced more severe infections, while some patients on the triple combination reported more frequent heart-related events.
It is important to remember that this study focused on a specific group of people with CLL who did not have certain genetic markers. Because it is a single trial, these results may not apply to every person with leukemia. Additionally, because overall survival did not change significantly between the groups, the primary benefit found was in the length of time patients lived without their disease worsening. For now, these findings suggest that venetoclax-based combinations are a strong option for extending the time a patient stays stable on treatment.
